{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-284303","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.295187+00:00","generated_at":"2026-06-07T21:13:30.028696+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Neumora receives FDA IND clearance for NMRA-266; starts Phase 1","bullets":["NMRA-266 is a positive allosteric modulator of M4 muscarinic receptor, licensed from Vanderbilt University.","Phase 1 SAD/MAD study initiated in healthy adults after FDA IND clearance on Nov 27, 2023.","First clinical trial for NMRA-266; aims to evaluate safety, tolerability, and pharmacokinetics.","Neumora focuses on neuroscience; NMRA-266 could treat schizophrenia and other CNS disorders."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-284303","json":"https://secwatch.observer/filing/0001193125-23-284303.json","markdown":"https://secwatch.observer/filing/0001193125-23-284303.md","text":"https://secwatch.observer/filing/0001193125-23-284303.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312523284303/0001193125-23-284303-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312523284303/d614921d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:13:30.028696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}